Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9.
about
PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6CYP2B6 gene single nucleotide polymorphisms and leukemia susceptibilityPopulation pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects.Auto-induction of phase I and phase II metabolism of artemisinin in healthy Chinese subjects after oral administration of a new artemisinin-piperaquine fixed combination.Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducersPreliminary investigation of the contribution of CYP2A6, CYP2B6, and UGT1A9 polymorphisms on artesunate-mefloquine treatment response in Burmese patients with Plasmodium falciparum malaria.CYP2B6: new insights into a historically overlooked cytochrome P450 isozymeCarboxymefloquine, the major metabolite of the antimalarial drug mefloquine, induces drug-metabolizing enzyme and transporter expression by activation of pregnane X receptor.Discovery, mechanisms of action and combination therapy of artemisininPrevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New GuineaPharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6.Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevancePrevalence of poor and rapid metabolizers of drugs metabolized by CYP2B6 in North Indian population residing in Indian national capital territory.Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinicalInhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.Parasite Clearance and Artemether Pharmacokinetics Parameters Over the Course of Artemether-Lumefantrine Treatment for Malaria in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Ugandan Children.A Toxicologist's Guide to the Preclinical Assessment of Hepatic Microsomal Enzyme Induction.Hepatic drug-metabolizing enzyme induction and implications for preclinical and clinical risk assessment.Methods for the quantitative evaluation and prediction of CYP enzyme induction using human in vitro systems.Induction of cytochrome P450 enzymes: a view on human in vivo findings.Evaluation of pregnane X receptor (PXR)-mediated CYP3A4 drug-drug interactions in drug development.In vitro drug metabolism testing using blood-monocyte derivatives.Population pharmacokinetic properties of artemisinin in healthy male Vietnamese volunteers.Retrospective analysis of artemisinin pharmacokinetics: application of a semiphysiological autoinduction model.First assessment in humans of the safety, tolerability, pharmacokinetics, and ex vivo pharmacodynamic antimalarial activity of the new artemisinin derivative artemisonePopulation pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer.Effects of artemisinin antimalarials on Cytochrome P450 enzymes in vitro using recombinant enzymes and human liver microsomes: potential implications for combination therapies.Modulation of Cytochrome P450, P-glycoprotein and Pregnane X Receptor by Selected Antimalarial Herbs-Implication for Herb-Drug Interaction.Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects.In vivo and mechanistic evidence of nuclear receptor CAR induction by artemisinin.
P2860
Q27012807-49208C3F-8B1A-4C8E-9DE7-C0ED482695F7Q28294323-9696B158-F16A-4141-AEBD-21C68B9F87FDQ33590189-CCF42C82-7D09-497D-8C12-BE2513338467Q33746978-56006E75-5CBD-4CFE-B8D9-8504E61D720DQ33881813-4F814248-E964-461E-9BCD-F22A84037CF7Q34015980-98EDEC4C-50C0-4412-AE91-353BA0868610Q34824471-3C28AE65-108F-4FCF-9713-68CE5DF7EEF1Q34921957-D7C52A5E-89B8-4966-B316-7570C4F76F99Q35006418-DBB54A10-7D93-4A30-988E-448FE5009B96Q35669950-A234CAB8-E94C-4D2B-968B-BE70DA336F00Q36365500-CDA945B6-56FB-4BF1-9F82-CFAFC40A9ADEQ36657589-0701B3BA-5EBD-4732-A8D2-3C2681493D8BQ37052162-C1D2FCF3-42A3-4EDD-BB81-5EC3BBC96C34Q37237446-402EC65D-CF5C-4981-BC9F-C953CC4F2E7FQ37358704-FDAE96A7-4936-495C-986D-82D9463FB870Q37517983-C7C764ED-7D22-43D8-8E55-07E95CF9B6F9Q37658729-9A3D38D6-3F12-47F4-8088-A0E9E65EB30EQ37771144-1B3DD667-D67F-451A-B4D6-0E196B5FA18BQ38028549-26B21563-85EF-46A1-88DB-7E2DB585CAFEQ38057372-0E10B2D4-CD63-4378-B538-9CA202BF2CEAQ38074989-22230120-66C7-4B97-A3D1-6AC61E613828Q38132218-F7446884-4CB7-4BF2-B77E-5D759AEB05D0Q38487882-A7611BE6-CF41-4F71-9AEB-7980E8E3A6C9Q41117898-4A0B3F43-AE08-471F-AC94-850E69A85262Q42445249-5641279F-17C6-4045-AA3A-6E6BEF96BBCEQ44872854-ECE53EEF-B3AA-443A-8913-30C0D1FBFB16Q45976136-09D64728-D419-4829-A8A4-4010DFC351C5Q46260895-2C73A7BF-DAEF-4D85-B63F-0C21FFF33C88Q47833388-DFC13CB6-ADFF-4385-A70A-F5344CF1FB33Q48034439-64134C7C-456C-4527-A476-30500B17F2FB
P2860
Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9.
@en
Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9.
@nl
type
label
Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9.
@en
Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9.
@nl
prefLabel
Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9.
@en
Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9.
@nl
P2093
P1476
Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9
@en
P2093
Britt Jansson
Dinh Xuan Huong
Gunnel Tybring
Michael Ashton
Trinh Ngoc Hai
P356
10.1016/S0009-9236(03)00092-4
P407
P577
2003-07-01T00:00:00Z